Literature DB >> 19718633

Renal outcomes after liver transplantation in the model for end-stage liver disease era.

Pratima Sharma1, Kathy Welch, Richard Eikstadt, Jorge A Marrero, Robert J Fontana, Anna S Lok.   

Abstract

The proportion of patients undergoing liver transplantation (LT) with renal insufficiency has significantly increased in the Model for End-Stage Liver Disease (MELD) era. This study was designed to determine the incidence and predictors of post-LT chronic renal failure (CRF) and its effect on patient survival in the MELD era. Outcomes of 221 adult LT recipients who had LT between February 2002 and February 2007 were reviewed retrospectively. Patients who were listed as status 1, were granted a MELD exception, or had living-donor, multiorgan LT were excluded. Renal insufficiency at LT was defined as none to mild [estimated glomerular filtration rate (GFR) >or= 60 mL/minute], moderate (30-59 mL/minute), or severe (<30 mL/minute). Post-LT CRF was defined as an estimated GFR < 30 mL/minute persisting for 3 months, initiation of renal replacement therapy, or listing for renal transplantation. The median age was 54 years, 66% were male, 89% were Caucasian, and 43% had hepatitis C. At LT, the median MELD score was 20, and 6.3% were on renal replacement therapy. After a median follow-up of 2.6 years (range, 0.01-5.99), 31 patients developed CRF with a 5-year cumulative incidence of 22%. GFR at LT was the only independent predictor of post-LT CRF (hazard ratio = 1.33, P < 0.001). The overall post-LT patient survival was 74% at 5 years. Patients with MELD >or= 20 at LT had a higher cumulative incidence of post-LT CRF in comparison with patients with MELD < 20 (P = 0.03). A decrease in post-LT GFR over time was the only independent predictor of survival. In conclusion, post-LT CRF is common in the MELD era with a 5-year cumulative incidence of 22%. Low GFR at LT was predictive of post-LT CRF, and a decrease in post-LT GFR over time was associated with decreased post-LT survival. Further studies of modifiable preoperative, perioperative, and postoperative factors influencing renal function are needed to improve outcomes following LT. (c) 2009 AASLD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19718633     DOI: 10.1002/lt.21821

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  38 in total

1.  Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.

Authors:  Thomas D Boyer; Arun J Sanyal; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Veit Gülberg; Samuel Sigal; Alice S Bexon; Peter Teuber
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

2.  Patient-specific prediction of ESRD after liver transplantation.

Authors:  Pratima Sharma; Nathan P Goodrich; Douglas E Schaubel; Mary K Guidinger; Robert M Merion
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

3.  Impact of MELD-based allocation on end-stage renal disease after liver transplantation.

Authors:  P Sharma; D E Schaubel; M K Guidinger; N P Goodrich; A O Ojo; R M Merion
Journal:  Am J Transplant       Date:  2011-08-22       Impact factor: 8.086

Review 4.  Model for End-stage Liver Disease.

Authors:  Ashwani K Singal; Patrick S Kamath
Journal:  J Clin Exp Hepatol       Date:  2012-12-01

Review 5.  Model for end-stage liver disease: end of the first decade.

Authors:  Sumeet K Asrani; W Ray Kim
Journal:  Clin Liver Dis       Date:  2011-10-01       Impact factor: 6.126

6.  An emerging population: kidney transplant candidates who are placed on the waiting list after liver, heart, and lung transplantation.

Authors:  Titte R Srinivas; Brian R Stephany; Marie Budev; David P Mason; Randall C Starling; Charles Miller; David A Goldfarb; Stuart M Flechner; Emilio D Poggio; Jesse D Schold
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-02       Impact factor: 8.237

7.  Underestimation of chronic renal dysfunction after liver transplantation: ICEBERG study.

Authors:  Evaristo Varo; Rafael Bañares; Magda Guilera
Journal:  World J Transplant       Date:  2015-03-24

8.  Native kidney function following liver transplantation using calcineurin inhibitors: single-center analysis with 20 years of follow-up.

Authors:  John C LaMattina; Joshua D Mezrich; Luis A Fernandez; Anthony M D'Alessandro; Arjang Djamali; Alexandru I Musat; John D Pirsch; David P Foley
Journal:  Clin Transplant       Date:  2013-01-07       Impact factor: 2.863

9.  Study protocol: a pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients with impaired renal function. PATRON-study.

Authors:  Andreas A Schnitzbauer; Marcus N Scherer; Justine Rochon; Johannes Sothmann; Stefan A Farkas; Martin Loss; Edward K Geissler; Aiman Obed; Hans J Schlitt
Journal:  BMC Nephrol       Date:  2010-09-14       Impact factor: 2.388

10.  Short-term pretransplant renal replacement therapy and renal nonrecovery after liver transplantation alone.

Authors:  Pratima Sharma; Nathan P Goodrich; Min Zhang; Mary K Guidinger; Douglas E Schaubel; Robert M Merion
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-28       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.